KeifeRx Employee Directory
Biotechnology ResearchVirginia, United States2-10 Employees
KeifeRx is a clinical-stage biotechnology company based in McLean, Virginia, focused on discovering and developing orally delivered, low-dose tyrosine kinase inhibitors for neurodegenerative and immune diseases. Its approach centers on brain-penetrant inhibitors intended to restore autophagy and reduce neuroinflammation, with a pipeline described as novel and optimized. Operating with a small team, the company has expanded an exclusive licensing agreement with Georgetown University to include multiple disease indications for its portfolio of novel tyrosine kinase inhibitors. The work targets patients affected by high-need neurological and immune conditions, supported by collaborations to broaden the potential applications of its therapies. In January 2026, KeifeRx announced that its CEO would speak at two leading investor events in San Francisco during J.P. Morgan Healthcare Conference week.